Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Established Cardiovascular Disease
NCT05669755Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in cardiovascular disease (CVD), sponsored by Novo Nordisk. Started Mar 2023; status: active, not recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05669755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669755.